Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune checkpoint blockade therapies have revolutionized cancer treatment but benefit only a subset of patients.
• Understanding mechanisms of immunotherapy resistance is critical for improving patient outcomes.

Purpose of the Study:

• To identify genes contributing to resistance against T cell-mediated tumor cell killing.
• To investigate the role of Decr2 in immunotherapy response and ferroptosis.

Main Methods:

• Genome-wide CRISPR screen to identify genes involved in T cell-mediated killing resistance.
• In vivo studies using anti-PD-L1 therapy with Decr2 knockdown.
• Analysis of ferroptosis markers and polyunsaturated ether phospholipids (PUFA-ePLs).
• Correlation analysis of Decr2 expression with anti-PD-1 therapy efficacy in human melanoma patient data.

Main Results:

• Decapping-2 (Decr2) was identified as a key gene in tumor cells mediating resistance to T cell killing.
• Decr2 knockdown reduced the efficacy of anti-PD-L1 immunotherapy in vivo.
• Reduced Decr2 expression diminished ferroptosis, linked to decreased PUFA-ePL induction.
• Upregulation of Decr2 correlated with anti-PD-1 efficacy in melanoma patients; Decr2 deletions predicted worse outcomes.

Conclusions:

• Decr2 is a critical regulator of immune-mediated tumor cell killing.
• Targeting Decr2 may offer a strategy to enhance the efficacy of cancer immunotherapies.